Blood-Brain Barrier Crossed: Denali's FDA Approval Unlocks Alzheimer'…

Denali Therapeutics' FDA approval of AVLAYAH in March 2026 demonstrates a validated platform for delivering large-molecule biologics across the blood-brain barrier using a transferrin receptor-based shuttle mechanism. The breakthrough opens a systemic drug delivery pathway for neurological diseases previously treatable only by surgery or intrathecal injection. If you're building a CNS therapeutic — enzyme, antibody, or gene therapy — you now have a proven delivery mechanism that doesn't require brain surgery or spinal injection. Denali just proved the transferrin receptor shuttle works at clinical scale; every biotech founder holding a molecule that couldn't reach the brain before now has a licensing partner and a customer willing to pay for access.